<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Urol</journal-id><journal-id journal-id-type="iso-abbrev">Adv Urol</journal-id><journal-id journal-id-type="publisher-id">AU</journal-id><journal-title-group><journal-title>Advances in Urology</journal-title></journal-title-group><issn pub-type="ppub">1687-6369</issn><issn pub-type="epub">1687-6377</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19190766</article-id><article-id pub-id-type="pmc">2630419</article-id><article-id pub-id-type="doi">10.1155/2009/419028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Role of Chemotherapy in Upper Tract Urothelial Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>O'Donnell</surname><given-names>Peter H.</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Stadler</surname><given-names>Walter M.</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1">Section of Hematology/Oncology, Department of Medicine, University of Chicago, Maryland Avenue, MC2115, Chicago, IL 60637, USA</aff><author-notes><corresp id="cor1">*Walter M. Stadler: <email>wstadler@medicine.bsd.uchicago.edu</email></corresp><fn fn-type="other"><p>Recommended by Norm D. Smith</p></fn></author-notes><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>1</month><year>2009</year></pub-date><volume>2009</volume><elocation-id>419028</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 P. H. O'Donnell and W. M. Stadler.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Locally advanced upper tract urothelial carcinoma has a poor prognosis. While surgery represents the only potentially curable therapeutic intervention, recurrences are common and typically systemic in nature. It is thus reasonable to consider perioperative chemotherapy in an effort to decrease the risk of recurrence. There are very little direct data providing clinical guidance in this scenario. For urothelial cancer of the bladder, there are randomized phase III data demonstrating a survival advantage with neoadjuvant cisplatin-based combination chemotherapy. Although arguments favoring adjuvant chemotherapy could be made for upper tract urothelial cancer, the loss of renal function that occurs with nephrectomy can complicate administration of appropriate perioperative treatment. Therefore, by analogy to urothelial carcinoma of the lower tract, it is argued that cisplatin-based neoadjuvant chemotherapy should be the standard of care for patients with locally advanced upper tract urothelial cancer.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Locally
advanced upper tract urothelial carcinoma has a poor prognosis. Surgical series suggest that, notwithstanding
nodal status, the disease-specific five-year survival rates for stages T2 and
T3 disease are 73% and 40%, respectively, while the median survival for T4
patients is approximately 6 months [<xref rid="B1" ref-type="bibr">1</xref>]. Importantly, the vast majority of patients with
invasive upper tract urothelial carcinoma have stage T3 or greater disease at
the time of surgery [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>], and, if investigated, at
least 20&#x02013;25% will have
lymph node involvement at the time of surgery [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. The poor prognosis is furthermore reflected
by mortality estimates in which the mortality to incidence ratio for upper tract
disease is approximately 0.34 [<xref rid="B7" ref-type="bibr">7</xref>], whereas for lower tract
urothelial cancer it is 0.20 [<xref rid="B8" ref-type="bibr">8</xref>]. This may be due in part to the notorious
difficulty of diagnosing earlier-stage urothelial cancer of the upper tract.</p><p>The
most common presenting symptom of upper tract urothelial carcinoma, like its
bladder counterpart, is hematuria [<xref rid="B1" ref-type="bibr">1</xref>]. Unfortunately, urine cytology is not
particularly sensitive for diagnosing urothelial carcinoma of any location [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Anterior grade and retrograde pyelogram, or ureteroscopy
with visualization of the renal pelvices, are technically challenging and not
routinely performed in the evaluation of hematuria. Computed tomography (CT) imaging is also not
very sensitive for early stage disease [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>].</p><p>While surgery
represents the only potentially curable therapeutic intervention for upper
tract urothelial cancer, systemic recurrences are common [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. It is thus reasonable to consider
perioperative chemotherapy in an effort to decrease the risk of recurrence. Unfortunately, with only approximately 2000 cases
annually in the United States [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B14" ref-type="bibr">14</xref>], and with the historical
difficulties in accruing urothelial carcinoma patients to clinical trials, there
are very little direct data providing clinical guidance in this scenario. Using
analogy to urothelial carcinoma of the lower tract, we believe that
cisplatin-based neoadjuvant chemotherapy should be the standard of care for
patients with locally advanced upper tract urothelial cancer.</p></sec><sec id="sec2"><title>2. Is Urothelial Cancer of the Upper Tract Different?</title><p>Bladder
and upper tract urothelial carcinomas have traditionally been considered
separate diseases in the urologic and surgical literature mainly because the
surgical approach to these diseases is so different. Yet, recent evidence has suggested that the
anatomic location of disease has no bearing on tumor behavior, in that recurrence
and mortality rates from upper and lower tract carcinomas are similar when
adjusted for tumor stage and grade [<xref rid="B15" ref-type="bibr">15</xref>]. Additionally, from a biologic prospective,
there is very little difference between urothelial carcinomas that arise from these
different sites. First of all, the most
important epidemiologic risk factor for urothelial cancer remains exposure to
tobacco products [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>], and this is true regardless
of the site of origin. Secondly, the
urothelial tissue itself is histologically indistinguishable by site [<xref rid="B18" ref-type="bibr">18</xref>]. Certainly, there are differences in the
underlying stroma and supportive tissue, but the importance of these
differences in the treatment of systemic disease, including the microscopic
systemic disease that is being targeted in perioperative therapy, is
debatable. Thirdly, the molecular
oncogenic events appear to be the same between upper and lower tract urothelial
cancers. For example, for both origins,
chromosome 9 deletions are the most common genetic abnormality [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>], and chromosome 9 and p53
alterations appear to be present at similar frequencies in upper and lower
tract lesions [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Fourth, it has been the practice of the
medical oncology community to include urothelial carcinoma patients in trials
of metastatic disease, regardless of the site of origin. A number of large studies have thus included
at least a fraction of patients whose initial tumor began in the upper tract 
[<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B27" ref-type="bibr">28</xref>]. In none of those studies was the site of
origin an important prognostic factor in the context of systemic
chemotherapy. Finally, the high incidence
of secondary (40&#x02013;50%), or, less
commonly, synchronous (8%) lower tract disease in patients with upper tract
disease [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B28" ref-type="bibr">29</xref>] also supports the notion that
these cancers actually represent one disease process in such patients. It is thus reasonable to consider systemic
and perioperative chemotherapy for locally advanced upper tract urothelial
cancer by analogy to urothelial cancer of the bladder.</p><p>For
urothelial cancer of the bladder, there are randomized phase III data
demonstrating a survival advantage with neoadjuvant cisplatin-based combination
chemotherapy. The two largest trials
were conducted by an international collaboration [<xref rid="B29" ref-type="bibr">30</xref>] and 
by Grossman et al. [<xref rid="B30" ref-type="bibr">31</xref>]. A meta-analysis including all neoadjuvant
chemotherapy trials confirms the conclusion [<xref rid="B31" ref-type="bibr">32</xref>]. Others have argued that the absolute benefit
of neoadjuvant chemotherapy is modest [<xref rid="B32" ref-type="bibr">33</xref>], and that the more accurate
clinical staging afforded by surgery [<xref rid="B33" ref-type="bibr">34</xref>] allows better patient
selection on the basis of prognostic factors [<xref rid="B34" ref-type="bibr">35</xref>]. Under the assumption of equivalent benefit
irrespective of underlying prognosis, the absolute benefit of perioperative chemotherapy
for poor prognosis patients is certainly going to be greater than that for good
prognosis patients. Nevertheless, the
randomized studies of adjuvant chemotherapy in urothelial cancer of the bladder
have been undersized and underpowered for detecting a clinically significant
benefit [<xref rid="B35" ref-type="bibr">36</xref>&#x02013;<xref rid="B39" ref-type="bibr">40</xref>].</p><p>Although
similar arguments favoring adjuvant chemotherapy could be made for upper tract
urothelial cancer, the loss of renal function that occurs with nephrectomy can
further complicate administration of appropriate perioperative treatment. In this regard, the above noted meta-analysis
[<xref rid="B31" ref-type="bibr">32</xref>] demonstrated survival 
benefits with neoadjuvant therapy only when
cisplatin-based combination chemotherapy was utilized, and two randomized
studies in the metastatic setting have strongly suggested that carboplatin,
which is typically substituted for cisplatin in patients with renal
dysfunction, is an inferior agent [<xref rid="B40" ref-type="bibr">41</xref>, <xref rid="B41" ref-type="bibr">42</xref>]. Furthermore, the decrement in renal function
associated with nephrectomy is not inconsequential, as evidenced by studies in
renal cancer patients undergoing nephrectomy [<xref rid="B42" ref-type="bibr">43</xref>, <xref rid="B43" ref-type="bibr">44</xref>]. This may be even more important in urothelial
cancer patients who are often smokers and have other smoking-related
comorbidities. Finally, anecdotal
experience and early evidence [<xref rid="B44" ref-type="bibr">45</xref>, <xref rid="B45" ref-type="bibr">46</xref>] suggest that even among patients
in whom neoadjuvant chemotherapy is indicated, only a minority actually receive
chemotherapy. This raises concerns about
a lack of adherence to chemotherapy recommendations [<xref rid="B46" ref-type="bibr">47</xref>] in the urologic community, or
perhaps an unwillingness by patients to be treated. Even if some urologists forgo neoadjuvant
chemotherapy referral in favor of future adjuvant administration, adherence
percentages in the postoperative setting are likely to be even lower, because
of both patient and surgeon factors [<xref rid="B47" ref-type="bibr">48</xref>, <xref rid="B48" ref-type="bibr">49</xref>]. Furthermore, despite hypothetical concerns
about the potential for increased surgical morbidity after neoadjuvant
chemotherapy, the data in bladder cancer patients have strongly demonstrated
that this does not occur [<xref rid="B48" ref-type="bibr">49</xref>, <xref rid="B49" ref-type="bibr">50</xref>], so we anticipate that the
same would be true for neoadjuvant chemotherapy in upper tract disease.</p></sec><sec id="sec3"><title>3. Conclusions</title><p>Upper
tract urothelial carcinoma, when not metastatic, typically presents with
locally advanced disease. Such disease
has a poor prognosis because of the high risk of systemic recurrence. Although the surgical approach to upper tract
and lower tract urothelial cancers is markedly different, the biology of these
diseases is for the most part indistinguishable. Certainly, the response to therapy appears to
be the same. Given the rarity of upper
tract urothelial cancer and the difficulty of accruing to clinical trials, recommendations
for perioperative chemotherapy must currently be based on similarities to its
lower tract counterpart. In this regard,
neoadjuvant chemotherapy is the standard of care based on improvements in
survival in well-conducted phase III trials. Such data does not exist with
adjuvant therapy in bladder cancer, and adjuvant therapy for upper tract
disease is further complicated by the difficulty of administering
cisplatin-based regimens to patients who may suffer a decrement in renal
function following nephrectomy. 
Therefore, until and unless specific trials are conducted, the most
reasonable standard for locally advanced upper tract urothelial cancer is
neoadjuvant, cisplatin-based combination chemotherapy prior to nephrectomy and
surgical resection.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MC</given-names></name><name><surname>Womack</surname><given-names>S</given-names></name><name><surname>Sagalowsky</surname><given-names>AI</given-names></name><name><surname>Carmody</surname><given-names>T</given-names></name><name><surname>Erickstad</surname><given-names>MD</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients</article-title><source><italic>Urology</italic></source><year>1998</year><volume>52</volume><issue>4</issue><fpage>594</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">9763077</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm&#x000e4;ng</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>SL</given-names></name></person-group><article-title>Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system</article-title><source><italic>Urology</italic></source><year>2005</year><volume>66</volume><issue>2</issue><fpage>274</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">16098355</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcneill</surname><given-names>SA</given-names></name><name><surname>Chrisofos</surname><given-names>M</given-names></name><name><surname>Tolley</surname><given-names>DA</given-names></name></person-group><article-title>The long-term outcome after laparoscopic nephroureterectomy: a comparison with open nephroureterectomy</article-title><source><italic>BJU International</italic></source><year>2000</year><volume>86</volume><issue>6</issue><fpage>619</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">11069365</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>H</given-names></name><name><surname>Kara</surname><given-names>I</given-names></name><name><surname>Gohji</surname><given-names>K</given-names></name><name><surname>Arakawa</surname><given-names>S</given-names></name><name><surname>Kamidono</surname><given-names>S</given-names></name></person-group><article-title>The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract</article-title><source><italic>British Journal of Urology</italic></source><year>1998</year><volume>82</volume><issue>4</issue><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">9806176</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbit</surname><given-names>L</given-names></name><name><surname>Gendreau</surname><given-names>M-C</given-names></name><name><surname>Mee</surname><given-names>S</given-names></name><name><surname>Cukier</surname><given-names>J</given-names></name></person-group><article-title>Tumors of the upper urinary tract: 10 years of experience</article-title><source><italic>The Journal of Urology</italic></source><year>1991</year><volume>146</volume><issue>5</issue><fpage>1243</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">1942271</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Nakazawa</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>F</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Toma</surname><given-names>H</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name></person-group><article-title>Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract</article-title><source><italic>Urology</italic></source><year>2007</year><volume>69</volume><issue>2</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17320661</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics, 2007</article-title><source><italic>CA: A Cancer Journal for Clinicians</italic></source><year>2007</year><volume>57</volume><issue>1</issue><fpage>43</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17237035</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="other"><collab>Surveillance Epidemiology and End Results (SEER) Database</collab><comment>Cancer of the Urinary Bladder Fact Sheet, Surveillance Research Program, National Cancer Institute, June 2008, <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov">http://seer.cancer.gov</ext-link></comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahal</surname><given-names>R</given-names></name><name><surname>Gogoi</surname><given-names>NK</given-names></name><name><surname>Sundaram</surname><given-names>SK</given-names></name></person-group><article-title>Is it necessary to perform urine cytology in screening patients with haematuria?</article-title><source><italic>European Urology</italic></source><year>2001</year><volume>39</volume><issue>3</issue><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">11275720</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanath</surname><given-names>S</given-names></name><name><surname>Zelhof</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Sethia</surname><given-names>K</given-names></name><name><surname>Mills</surname><given-names>R</given-names></name></person-group><article-title>Is routine urine cytology useful in the haematuria clinic?</article-title><source><italic>Annals of the Royal College of Surgeons of England</italic></source><year>2008</year><volume>90</volume><issue>2</issue><fpage>153</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">18325219</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scolieri</surname><given-names>MJ</given-names></name><name><surname>Paik</surname><given-names>ML</given-names></name><name><surname>Brown</surname><given-names>SL</given-names></name><name><surname>Resnick</surname><given-names>MI</given-names></name></person-group><article-title>Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma</article-title><source><italic>Urology</italic></source><year>2000</year><volume>56</volume><issue>6</issue><fpage>930</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">11113735</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caoili</surname><given-names>EM</given-names></name><name><surname>Cohan</surname><given-names>RH</given-names></name><name><surname>Inampudi</surname><given-names>P</given-names></name><etal/></person-group><article-title>MDCT urography of upper tract urothelial neoplasms</article-title><source><italic>American Journal of Roentgenology</italic></source><year>2005</year><volume>184</volume><issue>6</issue><fpage>1873</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">15908545</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassweiler</surname><given-names>JJ</given-names></name><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>Marrero</surname><given-names>R</given-names></name><name><surname>Frede</surname><given-names>T</given-names></name><name><surname>Redorta</surname><given-names>JP</given-names></name><name><surname>Bassi</surname><given-names>P</given-names></name></person-group><article-title>Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery?</article-title><source><italic>European Urology</italic></source><year>2004</year><volume>46</volume><issue>6</issue><fpage>690</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">15548434</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>JJ</given-names></name><name><surname>Ellison</surname><given-names>LM</given-names></name></person-group><article-title>Upper tract urothelial neoplasms: incidence and survival during the last 2 decades</article-title><source><italic>The Journal of Urology</italic></source><year>2000</year><volume>164</volume><issue>5</issue><fpage>1523</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">11025695</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catto</surname><given-names>JWF</given-names></name><name><surname>Yates</surname><given-names>DR</given-names></name><name><surname>Rehman</surname><given-names>I</given-names></name><etal/></person-group><article-title>Behavior of urothelial carcinoma with respect to anatomical location</article-title><source><italic>The Journal of Urology</italic></source><year>2007</year><volume>177</volume><issue>5</issue><fpage>1715</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">17437794</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Bogillot</surname><given-names>O</given-names></name><name><surname>Cordier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies</article-title><source><italic>International Journal of Cancer</italic></source><year>2000</year><volume>86</volume><issue>2</issue><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">10738259</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkes</surname><given-names>F</given-names></name><name><surname>Silveira</surname><given-names>TS</given-names></name><name><surname>Castro</surname><given-names>MG</given-names></name><name><surname>Cuck</surname><given-names>G</given-names></name><name><surname>Fernandes</surname><given-names>RC</given-names></name><name><surname>Perez</surname><given-names>MD</given-names></name></person-group><article-title>Carcinoma of the renal pelvis and ureter</article-title><source><italic>International Brazil Journal of Urology</italic></source><year>2006</year><volume>32</volume><issue>6</issue><fpage>648</fpage><lpage>655</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name></person-group><article-title>Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting</article-title><source><italic>Advances in Anatomic Pathology</italic></source><year>2008</year><volume>15</volume><issue>3</issue><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">18434765</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzai</surname><given-names>T-S</given-names></name><name><surname>Chen</surname><given-names>HH-W</given-names></name><name><surname>Chan</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>Clinical significance of allelotype profiling for urothelial carcinoma</article-title><source><italic>Urology</italic></source><year>2003</year><volume>62</volume><issue>2</issue><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">12893368</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname><given-names>C</given-names></name><name><surname>Knuechel</surname><given-names>R</given-names></name><name><surname>Zanardo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract</article-title><source><italic>Oncogene</italic></source><year>2001</year><volume>20</volume><issue>35</issue><fpage>4910</fpage><lpage>4915</lpage><pub-id pub-id-type="pmid">11521204</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>TD</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Eble</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Molecular evidence supporting field effect in urothelial carcinogenesis</article-title><source><italic>Clinical Cancer Research</italic></source><year>2005</year><volume>11</volume><issue>18</issue><fpage>6512</fpage><lpage>6519</lpage><pub-id pub-id-type="pmid">16166427</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>DS</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Kuzel</surname><given-names>TM</given-names></name><etal/></person-group><article-title>A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer</article-title><source><italic>Urologic Oncology: Seminars and Original Investigations</italic></source><year>2004</year><volume>22</volume><issue>5</issue><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">15464919</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von der Maase</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>SW</given-names></name><name><surname>Roberts</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2000</year><volume>18</volume><issue>17</issue><fpage>3068</fpage><lpage>3077</lpage><pub-id pub-id-type="pmid">11001674</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>CN</given-names></name><name><surname>de Mulder</surname><given-names>PHM</given-names></name><name><surname>Schornagel</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2001</year><volume>19</volume><issue>10</issue><fpage>2638</fpage><lpage>2646</lpage><pub-id pub-id-type="pmid">11352955</pub-id></element-citation></ref><ref id="B25a"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>A</given-names></name><name><surname>Aravantinos</surname><given-names>G</given-names></name><name><surname>Deliveliotis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2004</year><volume>22</volume><issue>2</issue><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">14665607</pub-id></element-citation></ref><ref id="B25b"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamias</surname><given-names>A</given-names></name><name><surname>Aravantinos</surname><given-names>G</given-names></name><name><surname>Deliveliotis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Erratum: docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2004</year><volume>22</volume><issue>9</issue><fpage>p. 1771</fpage></element-citation></ref><ref id="B26"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>D</given-names></name><name><surname>Raghavan</surname><given-names>D</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2000</year><volume>18</volume><issue>9</issue><fpage>1921</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">10784633</pub-id></element-citation></ref><ref id="B27"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreicer</surname><given-names>R</given-names></name><name><surname>Manola</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>100</volume><issue>8</issue><fpage>1639</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">15073851</pub-id></element-citation></ref><ref id="B28"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>JD</given-names></name><name><surname>Sosa</surname><given-names>RE</given-names></name><name><surname>Vaughan</surname><given-names>ED</given-names><suffix>Jr.</suffix></name><name><surname>Scherr</surname><given-names>DS</given-names></name></person-group><article-title>Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma</article-title><source><italic>Urology</italic></source><year>2007</year><volume>69</volume><issue>2</issue><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">17320658</pub-id></element-citation></ref><ref id="B29"><label>30</label><element-citation publication-type="journal"><collab>International Collaboration of Trialists</collab><article-title>Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial</article-title><source><italic>The Lancet</italic></source><year>1999</year><volume>354</volume><issue>9178</issue><fpage>533</fpage><lpage>540</lpage></element-citation></ref><ref id="B30"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>HB</given-names></name><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2003</year><volume>349</volume><issue>9</issue><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">12944571</pub-id></element-citation></ref><ref id="B31"><label>32</label><element-citation publication-type="journal"><collab>Advanced Bladder Cancer Meta-Analysis Collaboration</collab><person-group person-group-type="author"><name><surname>Vale</surname><given-names>C</given-names></name></person-group><article-title>Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis</article-title><source><italic>The Lancet</italic></source><year>2003</year><volume>361</volume><issue>9373</issue><fpage>1927</fpage><lpage>1934</lpage></element-citation></ref><ref id="B32"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feneley</surname><given-names>MR</given-names></name><name><surname>Harland</surname><given-names>S</given-names></name></person-group><article-title>Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a new standard of care?</article-title><source><italic>BJU International</italic></source><year>2003</year><volume>92</volume><issue>9</issue><fpage>877</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">14632837</pub-id></element-citation></ref><ref id="B33"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Yagoda</surname><given-names>A</given-names></name><name><surname>Herr</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion</article-title><source><italic>The Journal of Urology</italic></source><year>1988</year><volume>139</volume><issue>3</issue><fpage>470</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">3343728</pub-id></element-citation></ref><ref id="B34"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>PC</given-names></name><name><surname>Brown</surname><given-names>GA</given-names></name><name><surname>Grossman</surname><given-names>HB</given-names></name><name><surname>Dinney</surname><given-names>CP</given-names></name></person-group><article-title>Neoadjuvant chemotherapy for bladder cancer</article-title><source><italic>World Journal of Urology</italic></source><year>2006</year><volume>24</volume><issue>5</issue><fpage>531</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">17115230</pub-id></element-citation></ref><ref id="B35"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bono</surname><given-names>AV</given-names></name><name><surname>Benvenuti</surname><given-names>C</given-names></name><name><surname>Reali</surname><given-names>L</given-names></name><etal/></person-group><article-title>Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group</article-title><source><italic>Progress in Clinical and Biological Research</italic></source><year>1989</year><volume>303</volume><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">2675010</pub-id></element-citation></ref><ref id="B36"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinner</surname><given-names>DG</given-names></name><name><surname>Daniels</surname><given-names>JR</given-names></name><name><surname>Russell</surname><given-names>CA</given-names></name><etal/></person-group><article-title>The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial</article-title><source><italic>The Journal of Urology</italic></source><year>1991</year><volume>145</volume><issue>3</issue><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">1997689</pub-id></element-citation></ref><ref id="B37"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x000f6;ckle</surname><given-names>M</given-names></name><name><surname>Meyenburg</surname><given-names>W</given-names></name><name><surname>Wellek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study</article-title><source><italic>The Journal of Urology</italic></source><year>1992</year><volume>148</volume><issue>2, part 1</issue><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">1635123</pub-id></element-citation></ref><ref id="B38"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studer</surname><given-names>UE</given-names></name><name><surname>Bacchi</surname><given-names>M</given-names></name><name><surname>Biedermann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial</article-title><source><italic>The Journal of Urology</italic></source><year>1994</year><volume>152</volume><issue>1</issue><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8201695</pub-id></element-citation></ref><ref id="B39"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freiha</surname><given-names>F</given-names></name><name><surname>Reese</surname><given-names>J</given-names></name><name><surname>Torti</surname><given-names>FM</given-names></name></person-group><article-title>A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer</article-title><source><italic>The Journal of Urology</italic></source><year>1996</year><volume>155</volume><issue>2</issue><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">8558644</pub-id></element-citation></ref><ref id="B40"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogliotti</surname><given-names>L</given-names></name><name><surname>Carten&#x000ec;</surname><given-names>G</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial</article-title><source><italic>European Urology</italic></source><year>2007</year><volume>52</volume><issue>1</issue><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">17207911</pub-id></element-citation></ref><ref id="B41"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Eres</surname><given-names>N</given-names></name><etal/></person-group><article-title>Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma</article-title><source><italic>Cancer</italic></source><year>1997</year><volume>80</volume><issue>10</issue><fpage>1966</fpage><lpage>1972</lpage><pub-id pub-id-type="pmid">9366300</pub-id></element-citation></ref><ref id="B42"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>WKO</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Torres</surname><given-names>VE</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name></person-group><article-title>Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney</article-title><source><italic>Mayo Clinic Proceedings</italic></source><year>2000</year><volume>75</volume><issue>12</issue><fpage>1236</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">11126830</pub-id></element-citation></ref><ref id="B43"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKiernan</surname><given-names>J</given-names></name><name><surname>Simmons</surname><given-names>R</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name></person-group><article-title>Natural history of chronic renal insufficiency after partial and radical nephrectomy</article-title><source><italic>Urology</italic></source><year>2002</year><volume>59</volume><issue>6</issue><fpage>816</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">12031359</pub-id></element-citation></ref><ref id="B44"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>KA</given-names></name><name><surname>Milowsky</surname><given-names>MI</given-names></name><name><surname>Ritchey</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name></person-group><article-title>Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base</article-title><source><italic>The Journal of Urology</italic></source><year>2007</year><volume>178</volume><issue>2</issue><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">17561135</pub-id></element-citation></ref><ref id="B45"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Mitra</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the medicare population</article-title><source><italic>Urology</italic></source><year>2005</year><volume>65</volume><issue>6</issue><fpage>1118</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">15922428</pub-id></element-citation></ref><ref id="B46"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>CN</given-names></name><name><surname>Donat</surname><given-names>SM</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer</article-title><source><italic>Urology</italic></source><year>2007</year><volume>69</volume><issue>supplement 1</issue><fpage>62</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">17280909</pub-id></element-citation></ref><ref id="B47"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donat</surname><given-names>SM</given-names></name><name><surname>Shabsigh</surname><given-names>A</given-names></name><name><surname>Savage</surname><given-names>C</given-names></name><etal/></person-group><article-title>Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high volume tertiary cancer center experience</article-title><source><italic>European Urology</italic></source><year>2008</year><volume>55</volume><issue>1</issue><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">18640770</pub-id></element-citation></ref><ref id="B48"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millikan</surname><given-names>R</given-names></name><name><surname>Dinney</surname><given-names>C</given-names></name><name><surname>Swanson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2001</year><volume>19</volume><issue>20</issue><fpage>4005</fpage><lpage>4013</lpage><pub-id pub-id-type="pmid">11600601</pub-id></element-citation></ref><ref id="B49"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MC</given-names></name><name><surname>Swanson</surname><given-names>DA</given-names></name><name><surname>Dinney</surname><given-names>CPN</given-names></name></person-group><article-title>Complications of radical cystectomy: impact of the timing of perioperative chemotherapy</article-title><source><italic>Urology</italic></source><year>1996</year><volume>47</volume><issue>6</issue><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">8677571</pub-id></element-citation></ref></ref-list></back></article>